Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

About TransCode Therapeutics Forward-Looking Statements "The Company's regaining compliance with all Nasdaq's listing standards continues recent positive news for TransCode, following our announcement of positive blood test results in connection with our Phase 0 clinical trial and FDA authorization to proceed with our upcoming Phase 1 study. We believe our organization is prepared to continue to execute on our ambitious plans to swiftly advance our clinical development programs," said Tom Fitzgerald, TransC ...